Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two random groups of depressed out-patients were treated with either Maprotiline or the new antidepressant Lofepramine. The depressive state was assessed by using the Hamilton Depression Scale (HAM-D) before and after 1, 3 and 6 weeks of treatment. Both drugs produced remarkable improvement globally in total HAM-D score as well as in the symptom clusters. The differences in both groups are not significant, but compiling the results of adverse reactions and the therapeutic effect, the treatment outcome in the Lofepramine group was slightly superior.
 ...
PMID:[Double-blind comparison of the effects of a new tricyclic antidepressant (Lofepramine) and a tetracyclic antidepressant (maprotiline)]. 33 Apr 40

Maprotiline (Ludiomil) and doxepin were compared in the treatment of depression in a double-blind multicentre trial. Four centres and 95 in- and out-patients took part in the trial. The severity of depression was evaluated with the aid of a visual analogue scale and nine target symptoms. Both maprotiline and doxepin diminished neurotic as well as psychotic depression significantly. The mean time of onset of action was 7.0 days in the maprotiline group and 7.7 days in the doxepin group. No statistically significant differences in antidepressive effect were found between the treatments. Two patients in the maprotiline group and four patients in the doxepin group discontinued the treatment because of unwanted effects, one patient in each group because of lack of efficacy and nine patients due to reasons not related to the treatment.
 ...
PMID:Maprotiline and doxepin in the treatment of depression. A double-glind multicentre comparison. 34 85

Maprotiline (Ludiomil) is a dibenzo bicyclooctadiene pharmacologically related to the tricyclic antidepressants and stereochemically having a tetracyclic structure. A controlled, double-blind comparison of maprotiline and imipramine in a group of 71 female outpatients with primary depression is presented. Maprotiline was found to be at least as effective as imipramine and significantly better in depressive neurosis. It also showed a bipolar action, being effective in both agitation and retardation.
 ...
PMID:A controlled study of a tetracyclic antidepressant--maprotiline (Ludiomil). 109 69

A double blind comparison is reported of a new tetracyclic antidepressant, maprotiline, with amitriptyline and placebo in psychiatric outpatients. Amitriptyline was significantly more effective than placebo in its global effect on depression. Maprotiline emerged as neither inferior to amitriptyline nor superior to placebo. Methodological difficulties prevented an adequate assessment of the anxiolytic activity of maprotiline.
 ...
PMID:A controlled trial of maprotiline (Ludiomil) in depressed outpatients. 110 77

A clinical trial on fifty patients studied a new compound with a quadricyclic structure, Ciba 34.276-Ba or Maprotiline in any category of depression. The product was found to have notable antidepressive properties, capable to act on the melancholic depressions of the manic depressive psychosis and of involutive melancholia. The best results were noted in the neurotic and reactive depressions perhaps because a tranquilizing activity marked in the majority of the cases. The clinical tolerance was found good and the side effects which reminded of those caused by derivates of Imipramine, remained moderate while the biological tolerance was perfect. The modifications of the electroencephalogram were of two types, one of them suggesting thymoanaleptic activity, the other suggesting rather a sedative activity.
 ...
PMID:[Clinical and electroencephalographic study of a new antidepressive agent, mono-methyl-amino-propyl-dibenzo-bicyclo-octadine hydrochloride (Ciba 34, 276 Ba)]. 122 22

Prevention or reduction of suicide remains a serious challenge for the medical community. Psychotherapeutic and psychosocial interventions have not been shown to reduce the incidence of suicide attempts and analytic psychotherapy has been shown to increase suicidal behavior. The efficacy of pharmacotherapy in reducing suicide attempts in patients with a history of repeated suicidal behavior has been shown with low doses of the neuroleptic agent flupenthixol compared with placebo. Supporting findings have been reported with trifluoperazine. There is evidence to suggest that some antidepressants may not be neutral in their effect on suicidal behavior. Maprotiline, for example, was associated with an increase in suicide attempts compared with placebo in a large long-term treatment study despite its significant efficacy in preventing relapse of depression. Differential lethality indices taken from large community studies support the notion that noradrenergic drugs such as maprotiline, desipramine, and nortriptyline are associated with a higher than expected incidence of death from overdose, and the suicide-provoking potential may relate to some noradrenergic property. The studies of serotonergic antidepressants do not suggest that they are suicide-provoking agents; rather they appear to be neutral or protective. Prospective prophylactic studies are needed to test the ability of potential treatments for the reduction of suicidal behavior.
 ...
PMID:Pharmacotherapy in the prevention of suicidal behavior. 846 51

The increased heart rate is a frequent, seldom clinically significant side-effect of antidepressants. There are different opinions about the Maprotiline influence on the heart rate, either about its very existence or the pathophysiological mechanism of its side-effect. The aim of this study was to test the Maprotiline influence on the heart rate of depressed patients and to compare the results with the results of other studies. The study was carried out in a group of 21 patients with a depressive involutional syndrome treated by fixed daily doses of 150 mg of Maprotiline. The heart rate was estimated in a small sample of examinees using the method of paired observations, as a part of the orthostatic cardiovascular tolerance testing by Schellong's method; this was done before the therapy and twice a week during four week of the application of Maprotiline. The increase in the heart rate in the basal reclining position was noticed in 20 patients. The average value was 16 beats per minute. The increase of the heart rate was not noticed immediately after the application of the first doses but after the latency of 8 days on average. While increasing in the basal reclining position, the orthostatic deviation of the heart rate did not significantly change during the therapy. At the end of the study the orthostatic deviation even showed a negative sign. The reclining of the patients at the end of Schellong's test discovered a frequent occurrence of the prolonged blood pressure return from higher to normal values. The results obtained confirm the thesis that the increased heart rate in the therapy with Maprotiline is due to its noradrenergic activity, in other words, to its ability to block the "reuptake" of noradrenalin in the synaptic cleft. The delay of the heart rate increase in the basal reclining position, a more frequent prolonged blood pressure return in the further phase of the study, and the therapeutic response delay in the treatment of depression are explained by the authors by the same mechanism: by the most probable existence of the pathological changes in the synapses.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Maprotiline and the heart rate]. 209 38

Blood levels of Maprotiline were analysed and their relationship to the clinical response was examined in 89 depressed inpatients, according DSM III criteria for Major Depressive Episode, given the drug treatment for 3 weeks. Maprotiline produced marked decreases in mean MADRS and COVI scale scores by the end of treatment. On day 21, no correlation between blood levels of Maprotiline and MADRS or COVI scores were found when all patients were considered. Nevertheless, significant correlations were observed on day 14 (r = .22; p less than .05 for MADRS and r = .23; p less than .05 for COVI scale). In addition, a significant correlation between MADRS or COVI scale scores and Maprotiline blood levels were observed on days 14 and 21 in subgroups of young patients, severe depression (high scores to clinical global investigations), during of at least 3 months, treated without other drug than Maprotiline and good responders.
 ...
PMID:[Blood concentrations of maprotiline in depressive patients]. 305 53

In a double-blind study, 49 elderly patients with primary major depression, with or without cardiovascular disease, were treated with maprotiline or doxepin. Holter monitors, 12-lead ECGs, and orthostatic blood pressure measurements were used. Maprotiline was associated with decreased PVCs in patients with a "high" baseline rate, while doxepin was associated with increased PVCs in this group. There were no significant differences in orthostatic blood pressure changes between treatment and nontreatment phases or between the two drugs. Small but significant increases in heart rate and prolonged PR interval were noted with both drugs. QRS interval was prolonged by maprotiline but decreased by doxepin. Neither drug produced untoward effects in patients with stable angina or an old myocardial infarction. Maprotiline may have an antiarrhythmic effect which could be beneficial in the treatment of depression with concomitant PVCs. Conversely, doxepin may be more appropriate for depressed patients with heart block or intracardiac conduction delays. Further research is necessary to confirm these suggestions.
 ...
PMID:Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. 620 85

Twenty patients suffering from endogenous depression were treated with maprotiline for 4 weeks. Blood samples were collected at weekly intervals and severity of depression assessed using the Hamilton Depression Rating Scale. No simple relationship between plasma maprotiline concentration and amelioration score was observed at week 3 (rs = 0.25) or week 4 (rs = -0.05). No significant difference in plasma concentrations between responders and non-responders was observed at week 4. Maprotiline was effective as an antidepressant in some patients.
 ...
PMID:Maprotiline in affective illness. Plasma concentration and clinical response. 622 94


1 2 Next >>